Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
The role of bisphosphonates in the prevention and treatment of osteoporosis
Storm T., Thaborg G., Steinich T., Genant H.K., Sorense O.H. (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fractur rate in woment with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
Hesch R.D., Heck J., Delling G., Keck E., Reeve J., Canzler H., Schober O., Har H., Rittinghaus E.F. (1988) Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1–38) PTH and diphosphonate EHDP. Protocol study I, osteoporosis trial Hannover. Klin Wochenschr 66:976-984.
Pacifici R., Mac Murtry C., Vered I., Rupich R., Avioli L.V. (1988) Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 66:747-735.
Mallette L.E., Leblanc A.D., Pool J.L., Mechanick J.I. (1989) Cyclic therapy of osteoporosis with neutral phosphate and brief high-doses pulses of etidronate. J Bone Miner Res 4:143-149.
Hodsman A.B. (1989) Effect of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Minder 5:201-212.
Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C., Yanover M.J., Mysiw W.J., Kohse L., Rao M.B., Steiger P., Richmond B., Chesnut C. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
Anderson C., Cape R.D., Crilly R.G., Hodsman A.B., Wolfe B.M. (1984) Preliminary observations of a form of coherence therapy for osteoporosis. Calcif Tissue Int 36:341-343.
Smith M.L., Fogelman I., Hart D.M., Scott E., Bevan I., Leggate I. (1989) Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int 44:74-79.
Chesnut C.H., Genant H.K., Harris S.T., Jackson R.D., Licata A.A., Miller P.D., Ross P.D., Wasnich R.D. (1992) Etidronate cyclical therapy for treatment of postmenopausal osteoporosis: 4 year experience. J Bone Miner Res 7(1 S):143.
Miller P., Huffer W., Mac Intyre D., Yanover M., Anger M., Harrison M., Gillum D. (1992) Bone histomorphometry aften longterm treatment with cyclical phosphorus and etidronate. Bone Mine 17S1:23.
Jackson R.D., Harris S.T., Genant H.K., Watts N.B., Wasnich R.D., Licata A.A., Miller P.D., Chesnut C.H. (1992) Cyclical etidronate treatment of postmenopausal osteoporosis: 4 year experience. Bone Miner 17S1:154.
Storm T., Thaborg G., Kollerup G., Sorensen H.A., Genant H.K., Steiniche T., Melsen F., Sorensen O.H. (1992) Five years of intermittent, cyclical ctidronate therapy increases bone mass and reduces vertebral fracture rate in postmenopausal osteoporosis. Bone Miner 17S1:24.
Valkema R., Vismans F.J.E., Papopoulos S.E., Pauwels E.K.J., Bijvoet O.L.M. (1989) Maintained improvement in calcium balance and bone mineral contents in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183-192.
Devogelaer J.P., Nagant de Deuxchaisnes C. (1990) Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): non-linear increase of lumbar bonc mineral density. J. Bone Miner Res 5(2 S):251.
Passeri M., Baroni M.C., Pedrazzoni M., Pioli G., Barbagallo M., Costi D., Biondi M., Girasole G., Arlunno B., Palummeri E. (1991) Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-248.
Devogclaer J.P., Esselinckx W., Nagant de Deuxchaisnes C. (1990) A randomized, controlled trial of APD (Disodium pamidronate), given intravenously with and without sodium fluoride in involutional osteoporosis. J Bone Miner Res 5(2 S):252.
Reginster J.Y., Lecart M.P., Deroisy R., Sarlet N., Denis D., Ethgen D., Collette J., Franchimont P. (1989) Prevention of postmenopausal bone loss by Tiludronate. Lancet 2:1469-1471.
Reginster J.Y. (1992) Oral tiludronate: pharmacological properties an potential usefulness in Paget's disease of bone and osteoporosis. Bone 13:351-354.
Geusens P., Nijs J., Van Der Perre G., Van Auderkercke R., Lowet G., Goovaerts S., Barbier A., Lacheretz F., Remandct B., Jiang Y., Dequeker J. (1992) Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in momkeys. J Bone Miner Res 7:599-609.
Reginster J.Y., Colson F., Morlock G., Combes B., Ethgen D., Geusens P. (1992) Evaluation of efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, dose ranging, placebo-controlled study. Arthritis Rheum 35:967-974.
Harris S.T., Gertz B.J., Genant H.K., Eyre D.R., Survili T.T., Ventura J.N., Debrock J., Ricera E., Chesnut C.H. (1993) The effect of short term treatment wit alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406.
Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., Rodan G., Hayes W.C. (1992) Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7:1399-1406.
Apseloff G., Girten B., Weisbrode S.E., Walker M., Stern L.S., Krecic M.E., Gerber N. (1993) Effects of aminohydroxybutane bisphosphonate on bone growth when administered after hind-limb bone in tail-suspended rats. J Pharmacol Exp Ther 267:515-521.
Wronski T.J., Yen C.F., Scott K.S. (1991) Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 6:387-394.